Why the study?
Do elevations in Troponin I and C-Reactive Protein predict congestive heart failure in breast cancer patients treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib?
Do elevations in Troponin I and C-Reactive Protein predict congestive heart failure in breast cancer patients treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib?
In breast cancer patients receiving dose-dense chemotherapy with trastuzumab and lapatinib, troponin I elevations are common and may precede LVEF declines, but they do not reliably predict clinical congestive heart failure.
Troponin I should not guide heart failure risk assessment in this setting; leaves open validation of predictive biomarkers during dual HER2 blockade.
In patients receiving ddAC → PTL, cTnIs are commonly detected. These elevations may precede changes in LVEF but, as assessed in this trial, do not predict CHF.
No takes yet. Share an insight, caveat, or question.
Morris et al. (2011) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: